Literature DB >> 24566186

Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry.

Elena Maryka Maiolo1, Ulrika Furustrand Tafin, Olivier Borens, Andrej Trampuz.   

Abstract

We investigated the activities of fluconazole, caspofungin, anidulafungin, and amphotericin B against Candida species in planktonic form and biofilms using a highly sensitive assay measuring growth-related heat production (microcalorimetry). C. albicans, C. glabrata, C. krusei, and C. parapsilosis were tested, and MICs were determined by the broth microdilution method. The antifungal activities were determined by isothermal microcalorimetry at 37°C in RPMI 1640. For planktonic Candida, heat flow was measured in the presence of antifungal dilutions for 24 h. Candida biofilm was formed on porous glass beads for 24 h and exposed to serial dilutions of antifungals for 24 h, and heat flow was measured for 48 h. The minimum heat inhibitory concentration (MHIC) was defined as the lowest antifungal concentration reducing the heat flow peak by ≥50% (≥90% for amphotericin B) at 24 h for planktonic Candida and at 48 h for Candida biofilms (measured also at 24 h). Fluconazole (planktonic MHICs, 0.25 to >512 μg/ml) and amphotericin B (planktonic MHICs, 0.25 to 1 μg/ml) showed higher MHICs than anidulafungin (planktonic MHICs, 0.015 to 0.5 μg/ml) and caspofungin (planktonic MHICs, 0.125 to 0.5 μg/ml). Against Candida species in biofilms, fluconazole's activity was reduced by >1,000-fold compared to its activity against the planktonic counterparts, whereas echinocandins and amphotericin B mainly preserved their activities. Fluconazole induced growth of planktonic C. krusei at sub-MICs. At high concentrations of caspofungin (>4 μg/ml), paradoxical growth of planktonic C. albicans and C. glabrata was observed. Microcalorimetry enabled real-time evaluation of antifungal activities against planktonic and biofilm Candida organisms. It can be used in the future to evaluate new antifungals and antifungal combinations and to study resistant strains.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24566186      PMCID: PMC3993256          DOI: 10.1128/AAC.00057-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

Review 1.  Antifungal agents: mechanisms of action.

Authors:  Frank C Odds; Alistair J P Brown; Neil A R Gow
Journal:  Trends Microbiol       Date:  2003-06       Impact factor: 17.079

Review 2.  Treatment of infections associated with surgical implants.

Authors:  Rabih O Darouiche
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 3.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

4.  Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms.

Authors:  Gordon Ramage; Stefano Bachmann; Thomas F Patterson; Brian L Wickes; José L López-Ribot
Journal:  J Antimicrob Chemother       Date:  2002-06       Impact factor: 5.790

5.  Resistance of Candida albicans biofilms to antifungal agents in vitro.

Authors:  S P Hawser; L J Douglas
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.

Authors:  Stéphane Corvec; Ulrika Furustrand Tafin; Bertrand Betrisey; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

7.  Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.

Authors:  D Sanglard; F Ischer; J Bille
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Uses and limitations of the XTT assay in studies of Candida growth and metabolism.

Authors:  D M Kuhn; M Balkis; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  12 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Promising Anti-Biofilm Agents and Phagocytes Enhancers for the Treatment of Candida albicans Biofilm-Associated Infections.

Authors:  Yasmine H Tartor; Gamal A Elmowalid; Mohamed N Hassan; Asmaa Shaker; Dalia F Ashour; Taisir Saber
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

3.  Influence of culture media on biofilm formation by Candida species and response of sessile cells to antifungals and oxidative stress.

Authors:  Isela Serrano-Fujarte; Everardo López-Romero; Georgina Elena Reyna-López; Ma Alejandrina Martínez-Gámez; Arturo Vega-González; Mayra Cuéllar-Cruz
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

4.  Reduced ability to detect surface-related biofilm bacteria after antibiotic exposure under in vitro conditions.

Authors:  Christen Ravn; Ulrika Furustrand Tafin; Bertrand Bétrisey; Søren Overgaard; Andrej Trampuz
Journal:  Acta Orthop       Date:  2016-10-24       Impact factor: 3.717

5.  Thermogenic Characterization and Antifungal Susceptibility of Candida auris by Microcalorimetry.

Authors:  Mariagrazia Di Luca; Anna Koliszak; Svetlana Karbysheva; Anuradha Chowdhary; Jacques F Meis; Andrej Trampuz
Journal:  J Fungi (Basel)       Date:  2019-11-06

6.  Antifungal Effect of Novel 2-Bromo-2-Chloro-2-(4-Chlorophenylsulfonyl)-1-Phenylethanone against Candida Strains.

Authors:  Monika Staniszewska; Małgorzata Bondaryk; Magdalena Wieczorek; Eine Estrada-Mata; Héctor M Mora-Montes; Zbigniew Ochal
Journal:  Front Microbiol       Date:  2016-08-25       Impact factor: 5.640

7.  Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.

Authors:  Célia F Rodrigues; Mariana Henriques
Journal:  Pathogens       Date:  2017-12-01

8.  Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control.

Authors:  Eddie Dominguez; Robert Zarnowski; Hiram Sanchez; Antonio S Covelli; William M Westler; Parastoo Azadi; Jeniel Nett; Aaron P Mitchell; David R Andes
Journal:  mBio       Date:  2018-04-03       Impact factor: 7.867

9.  Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma.

Authors:  Wilson Lim; Youri Melse; Mickey Konings; Hung Phat Duong; Kimberly Eadie; Benoît Laleu; Benjamin Perry; Matthew H Todd; Jean-Robert Ioset; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2018-04-26

10.  Insight into the Antifungal Mechanism of Action of Human RNase N-terminus Derived Peptides.

Authors:  Vivian A Salazar; Javier Arranz-Trullén; Guillem Prats-Ejarque; Marc Torrent; David Andreu; David Pulido; Ester Boix
Journal:  Int J Mol Sci       Date:  2019-09-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.